Science Corporation implants its vision-restoring chip in its first Stargardt disease patient

Science Corporation announced the implantation of its visual restoration chip in the first patient diagnosed with Stargardt disease, a hereditary macular degeneration that causes progressive vision loss. The procedure, performed by the company’s medical team, used a miniature electrode array that connects directly to the optic nerve, aiming to stimulate remaining visual cells and transmit signals to the brain. According to project leaders, the implant builds on technology previously developed for brain‑computer interfaces (BCI) and marks a significant step toward treatments that blend neuroscience and electronics to correct sensory deficits.

The announcement was made at the TechCrunch Disrupt conference, where Max Hodak, former head and co‑founder of Neuralink, explained that the partnership with PRIMA is part of the company’s path toward more advanced neural interfaces. Hodak emphasized that the insights gained from this clinical case will provide valuable data to refine the chip’s design and assess its long‑term safety and effectiveness.

This development is important because it opens the door to BCI‑based therapies for currently incurable eye diseases and could lay the groundwork for future therapeutic applications that integrate electronic devices with the central nervous system.

Read the original article on TechCrunch AI

This summary is an informational synthesis produced by dataqbs.com. All rights to the original content belong to its author and the cited media outlet. We act solely as curators of technology news and claim no authorship.